A61K 2239/58
Prostate
A61K2239/58 (Prostate) appears on 108 US grants and 250 published applications in this corpus.
Search patents in A61K- Granted patents
- 108
- Published applications
- 250
- Assignees
- 127
- Inventors
- 475
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 7 |
| 2003 | 1 | 6 |
| 2004 | 2 | 6 |
| 2005 | 1 | 5 |
| 2006 | 3 | 6 |
| 2007 | 1 | 5 |
| 2008 | 1 | 10 |
| 2009 | 3 | 5 |
| 2010 | 2 | 6 |
| 2011 | 3 | 8 |
| 2012 | 4 | 12 |
| 2013 | 3 | 11 |
| 2014 | 7 | 7 |
| 2015 | 7 | 14 |
| 2016 | 5 | 8 |
| 2017 | 6 | 5 |
| 2018 | 8 | 11 |
| 2019 | 5 | 11 |
| 2020 | 5 | 12 |
| 2021 | 4 | 17 |
| 2022 | 2 | 14 |
| 2023 | 3 | 12 |
| 2024 | 13 | 21 |
| 2025 | 7 | 13 |
| 2026 | 8 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Composition of NY-ESO-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules5 May 2026US 12,617,834 B2California Institute of Technology
- PSMA-targeted immunotherapies for cancers21 Apr 2026US 12,605,446 B2The Methodist Hospital
- Compositions and methods for anti-TnMUC1 gold CAR t-cells17 Mar 2026US 12,576,135 B2Chimera Bioengineering, Inc.
- CAR T-cells for the treatment of bone metastatic cancer10 Mar 2026US 12,569,507 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
- Prostate-specific membrane antigen targeted nf-kb p50-deficient immature myeloid cells27 Aug 2026US 2026/0248849 A1The Johns Hopkins University
- Synthetic antigen receptors for covalent immune recruiters and methods and uses thereof27 Aug 2026US 2026/0248852 A1McMaster University
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242480 A1Centre National de la Recherche Scientifique (CNRS)
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242483 A1Centre National de la Recherche Scientifique (CNRS)
Most cited
By later US patents
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool110US 8,637,307 B2The Trustees of the University of Pennsylvania · 2014
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool81US 7,745,140 B2The Trustees of the University of Pennsylvania · 2010
- Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy72US 5,788,963 APacific Northwest Cancer Foundation · 1998
- Activation and expansion of T-cells using an engineered multivalent signaling platform69US 7,638,326 B2The Trustees of the University of Pennsylvania · 2009
- Method for isolating dendritic cells64US 5,643,786 AThe United States of America as represented by the Department of Health and Human Services · 1997